Allergic Rhinitis
Conditions
Interventions
Treatment group :Needling Sphenopalatine Ganglion
Control group:puncturing Xiaguan acupoint
Sponsors
Beijing Tongren Hospital affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1: Clear diagnosis, with the age of 18-60 years old 2: Have a history of typical allergic rhinitis for more than 2 years and more than 10 years 3: Nasal secretion smear or peripheral blood IgE test is positive 4: The duration of the disease lasts for at least 6 weeks in each attack 5: Agree to follow the treatment plan, be able to understand and actively cooperate with the acupuncture treatment 6: Voluntary signing of the informed consent form.
Exclusion criteria
Exclusion criteria: 1: The following guan points are those with skin damage and infection within the 2cm radius of the center and are not suitable for acupuncture 2: Patients currently receiving allergen-specific immunotherapy 3: Treatment with ß receptor blockers (including systemic and topical medication) 4: Allergic rhinitis combined with moderate and severe asthma (FEV1 5: Patients who have received oral antihistamine drugs within the first 2 weeks of selection 6: Oral corticosteroids were used within the first 4 weeks of selection 7: Respiratory tract infection within the first 4 weeks of selection 8: Have participated in other clinical trials within 3 months 9: Patients with chronic sinusitis with / without nasal polyps, asthma and septum 10: Women with pregnancy period, lactation period and planned pregnancy 11: Patients with a history of immunosuppressive diseases (such as HIV infection), malignancy, autoimmune diseases, tuberculosis, cardiovascular insufficiency, or other serious organ systems as judged by the investigator 12: Other circumstances that the investigator considers is not suitable to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nasal resistance;Nasal resistance;Rhinitis (conjunctivitis) symptom score;The NF- ? B signaling pathway activation state;TNF-a?IgE?IL-10;lncRNA-mRNA; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of Survival Questionnaire; | — |
Countries
China
Contacts
Public ContactZhang Peng
Beijing Tongren Hospital affiliated to Capital Medical University
Outcome results
None listed